Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2018-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV

NCT04550676

Hiv Fatigue Mobility Limitation

ACTIVE_NOT_RECRUITING NA

Feasibility of an Exercise Intervention

NCT01984060

HIV

COMPLETED NA

Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV

NCT01860261

HIV

COMPLETED NA

Feasibility of HIIT in Older Adults with HIV and Hypertension

NCT06888596

HIV Hypertension Exercise

COMPLETED NA

Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV

NCT06013579

HIV Infections Cognitive Impairment

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with HIV. Both HIV-infected and HIV-uninfected older adults will be assigned to a moderate intensity cardiovascular and resistance training intervention for 12 weeks, and then randomized to either continue moderate intensity exercise, or increase to high intensity exercise for an additional 12 weeks. The primary outcome is the impact of exercise on physical function, as measured by the overall score of a modified Short Physical Performance Battery (mSPPB) and the chair rise time from the mSPPB. The secondary outcomes include changes in insulin-like growth factor-1 (systemic and local) and inflammation (interleukin-6 (IL-6), soluble tumor necrosis factor receptors 1 and 2 (sTNFR-1 and sTNFR-2)).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Inflammation Obesity Aging, Biological

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-uninfected

HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.

Group Type ACTIVE_COMPARATOR

High-intensity cardiovascular and resistance exercise

Intervention Type OTHER

Moderate-intensity cardiovascular and resistance exercise

Intervention Type OTHER

HIV-infected

HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.

Group Type EXPERIMENTAL

High-intensity cardiovascular and resistance exercise

Intervention Type OTHER

Moderate-intensity cardiovascular and resistance exercise

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-intensity cardiovascular and resistance exercise

Intervention Type OTHER

Moderate-intensity cardiovascular and resistance exercise

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 50-75
* HIV+ must be on ART for a minimum of 2 years with viral load \<200 copies/mL
* Sedentary
* cluster of differentiation 4 (CD4) T-cell count \>200 cells/microliter
* BMI \>19 and \<41
* Among females, must be post-menopausal
* Able to perform activities of daily living with out assistance

Exclusion Criteria

* Diabetes, poorly controlled with HgbA1c \>7.5; on insulin
* On growth hormone (or growth hormone axis) therapy, intramuscular testosterone, corticosteroids.
* Known active hepatitis B or C (viremia).
* Severe liver disease
* Uncontrolled hypertension (SPB \>180 or diastolic \>100).
* Underlying cardiac conditions that would make exercise or exercise testing potentially unsafe (unstable ischemic heart disease, Class III or IV heart failure clinically significant aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia)
* pulmonary disease requiring the use of supplemental oxygen ≥ 4 liters with physical exertion
* current diagnosis of malignancy (excluding non-melanoma skin cancers) within 48 weeks prior to enrollment
* surgery/trauma/injury/fracture within 24 weeks prior to enrollment that may impact a subject's ability to exercise
* history of stroke with residual deficits that may impact ability to exercise; orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly limit the ability to perform moderate-intensity resistance exercise (e.g., unable to be properly positioned in exercise equipment or to have severely restricted range of motion even after modifications have been made)
* weight over 300 pounds
* Montreal Cognitive Assessment (MOCA) score \< 18 (will be evaluated at screening visit after consent obtained)
* AIDS-defining opportunistic infection within the 24 weeks prior to enrollment
* Person who appear to have unstable health, are incapable of safely participating in the exercise intervention, or are felt to have a life expectancy of \< 1 year.
* Participants on anticoagulants (clopidogrel, Coumadin, etc) will be excluded from the muscle biopsy.
* Aspirin and Non-steroidal anti-inflammatory agents are not exclusions but should be stopped 1 week prior to muscle biopsy (subset of subjects).

Minimum Eligible Age

50 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes